Antitumor Activity of Ficlatuzumab in Combination with Tivozanib On Primary Human Renal Cell Carcinoma Xenografts

被引：0
|
作者：
Meetze, K. [1 ]
Connolly, K. [1 ]
Feng, B. [1 ]
Rideout, W. [1 ]
Gyuris, J. [1 ]
Han, M. [1 ]
机构：
[1] AVEO Pharmaceut Inc, Drug Discovery, Cambridge, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
301
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [21] Enhanced antitumor activity of 5-fluorouracil in combination with 2′-deoxyinosine in human colorectal cell lines and human colon tumor xenografts
    Ciccolini, J
    Peillard, L
    Evrard, A
    Cuq, P
    Aubert, C
    Pelegrin, A
    Formento, P
    Milano, G
    Catalin, J
    CLINICAL CANCER RESEARCH, 2000, 6 (04) : 1529 - 1535
  • [22] Antitumor effects of a combination of interferon-alpha and sorafenib oil human renal carcinoma cell lines
    Tochizawa, Shiro
    Masumori, Naoya
    Yanai, Yoshiaki
    Ohmoto, Yasukazu
    Yabuuchi, Youichi
    Tsukamoto, Taiji
    BIOMEDICAL RESEARCH-TOKYO, 2008, 29 (06): : 271 - 278
  • [23] Re: Cox-2 Inhibition Enhances the Activity of Sunitinib in Human Renal Cell Carcinoma Xenografts
    Atala, Anthony
    JOURNAL OF UROLOGY, 2013, 190 (03): : 1132 - 1132
  • [24] Tivozanib biomarker identifies tumor infiltrating myeloid cells contributing to tivozanib resistance in both preclinical models and human renal cell carcinoma
    Lin, J.
    Sun, X.
    Feng, B.
    Jiang, F.
    Li, G.
    Chiu, M. I.
    Esteves, B.
    Al-Adhami, M.
    Bhargava, P.
    Robinson, M. O.
    EJC SUPPLEMENTS, 2010, 8 (07): : 191 - 191
  • [25] Re: Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients with Renal Cell Carcinoma Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2012, 188 (06): : 2149 - 2150
  • [26] Intratumoral injection of arsenic to enhance antitumor efficacy in human esophageal carcinoma cell xenografts
    Shen, ZY
    Zhang, Y
    Chen, JY
    Chen, MH
    Shen, J
    Luo, WH
    Zeng, Y
    ONCOLOGY REPORTS, 2004, 11 (01) : 155 - 159
  • [27] Antitumor activity of irradiated riboflavin on human renal carcinoma cell line 786-O
    Chaves Neto, Antonio Hernandes
    Pelizzaro-Rocha, Karin Juliane
    Fernandes, Maruska Neufert
    Ferreira-Halder, Carmen Verissima
    TUMOR BIOLOGY, 2015, 36 (02) : 595 - 604
  • [28] Everolimus-bevacizumab combination has superior efficacy to either monotherapy in human renal cell carcinoma (RCC) xenografts
    McSheehy, Paul
    Ito, Moriko
    Cozens, Robert
    CANCER RESEARCH, 2009, 69
  • [29] The antitumor activity of lenvatinib (LEN) in combination with everolimus (EVE) in human renal cell carcinoma (RCC) xenograft models is dependent on VEGFR and FGFR signaling
    Kimura, T.
    Adachi, Y.
    Matsuki, M.
    Yamaguchi, A.
    Ozawa, Y.
    Okamoto, K.
    Mitsuhashi, K.
    Hoshi, T.
    Tohyama, O.
    Tai, K.
    Ogo, M.
    Matsui, J.
    Funahashi, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] TIVOZANIB: PRACTICAL IMPLICATIONS FOR RENAL CELL CARCINOMA AND OTHER SOLID TUMORS
    Berge, E. M.
    Bowles, D. W.
    Flaig, T. W.
    Lam, E. T.
    Jimeno, A.
    DRUGS OF TODAY, 2013, 49 (05) : 303 - 315
12345